Genus (LON:GNS - Get Free Report)'s stock had its "buy" rating restated by equities researchers at Shore Capital in a research note issued on Wednesday, MarketBeat.com reports.
Genus Price Performance
Shares of GNS stock traded up GBX 13 ($0.17) during trading hours on Wednesday, hitting GBX 2,005 ($26.61). The stock had a trading volume of 122,202 shares, compared to its average volume of 281,913. The company has a debt-to-equity ratio of 53.12, a current ratio of 1.80 and a quick ratio of 1.08. The stock has a market capitalization of £1.31 billion, a price-to-earnings ratio of 166.20, a PEG ratio of 2.87 and a beta of 0.37. Genus has a one year low of GBX 1,424 ($18.90) and a one year high of GBX 2,155 ($28.60). The stock's 50-day moving average price is GBX 1,794.82 and its two-hundred day moving average price is GBX 1,773.33.
Genus (LON:GNS - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported GBX 39.80 ($0.53) earnings per share (EPS) for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. Equities analysts forecast that Genus will post 70.9644323 EPS for the current year.
Insider Activity at Genus
In other news, insider Jorgen Kokke sold 19,967 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of GBX 1,731 ($22.97), for a total value of £345,628.77 ($458,636.90). 0.75% of the stock is owned by insiders.
Genus Company Profile
(
Get Free Report)
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Further Reading
Before you consider Genus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.
While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
